Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06302023

Enrollment

Registered

2024-03-08

Start date

2024-04-01

Completion date

2024-10-07

Last updated

2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant Women Diagnosed With Threatened Preterm Labor

Keywords

DHA, threatened preterm labor, Docosahexaenoic acid

Brief summary

The goal of this clinical trial is to learn about the effects of Docosahexaenoic acid (DHA) in reducing the incidence of premature birth in threatened preterm labor The main questions it aims to answer are: * Can DHA supplementation reduce the incidence of premature birth in threatened preterm labor? * How does DHA supplementation affect pregnancy outcomes? Participants were organized into two groups * Group 1 (Intervention) Participants will be asked to take a DHA 1000mg per day * Group 2 (control) Participant will not need to take a DHA

Detailed description

Threatened preterm labor is defined as regular uterine contractions occurring before 37 completed weeks of gestation, without any cervical dilation.

Interventions

DIETARY_SUPPLEMENTDocosahexaenoic acid (DHA) 1000 mg

Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Singleton pregnancy * Between 24 wk to 34 wk of gestational age * Pregnant women diagnosed threatened preterm labor (with no cervical change)

Exclusion criteria

* Fetal anomalies * Multiple pregnancy * Premature rupture of membrane * Placental disorders: placenta previa, placental abruption * Fetal growth restriction * Pregnancy complication: gestational diabetes mellitus, Chronic hypertension * Allergic reaction to DHA

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants with preterm birth	at delivery time	Delivery at less than 37 weeks of gestational age

Secondary

Measure	Time frame	Description
Rate of low birth weight neonate	at delivery time	Newborn's weight at birth is less than 2500g
Rate of Neonatal Intensive care unit admission	at delivery time	newborn need neonatal intensive care

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026